Please assess the completion status of the following clinical trial:

Trial Title: Mesenteric Sparing for the Prevention of Recurrent Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Residents of the United States~2. Isolated ileocolic Crohn's disease without evidence of perforation~3. Concurrent therapies with corticosteroids, 5-aminosalicylic acid (5-ASA) drugs, thiopurines, methotrexate (MTX), antibiotics, and anti-tumor necrosis factor (TNF) therapy are permitted~4. All patients should have undergone a colonoscopy and CT enterography in last 3 months to assess severity of disease~5. Have no contraindications to magnetic resonance (MR) evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia~6. Ability to comply with protocol~7. Competent and able to provide written informed consent~8. Medically refractory disease or inability to tolerate ongoing medical therapy~Exclusion Criteria:~1. Inability to give informed consent.~2. Patients undergoing repeat ileocolic resection~3. Patients with concurrent disease in other locations (e.g., proximal stricturing of the small bowel, fistulizing disease to the sigmoid colon) requiring additional operation intervention beyond an ileocolic resection~4. Clinically significant medical conditions within the six months before administration of Mesenchymal Stem Cells (MSCs): e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient~5. Specific exclusions;~   a. Evidence of hepatitis B, C, or HIV~6. History of cancer including melanoma (with the exception of localized skin cancers)~7. Emergent indication for an operation~8. A resident outside the United States~9. Pregnant or breast feeding.~10. History of clinically significant auto-immunity (other than Crohn's disease) or any previous example of fat-directed autoimmunity~11. Inability to follow up at Mayo Clinic at 3 to 4 and 12 months for postoperative imaging and endoscopy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Mesenteric sparing ileocolic resection (Type: ACTIVE_COMPARATOR): Ileocolic resection without removal of the lymph nodes in the mesentery.
- High ligation ileocolic resection (Type: ACTIVE_COMPARATOR): Ileocolic resection with removal of lymph nodes in the mesentery

Based on this trial design, predict the completion outcome and termination type (if applicable).